NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Informatica Inc. (NYSE: INFA) resulting from allegations that Informatica may have issued materially misleading business information to the investing public. So What: If you purchased Informatica securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme. ...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Trinseo PLC (NYSE: TSE) resulting from allegations that Trinseo may have issued materially misleading business information to the investing public. So What: If you purchased Trinseo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen. ...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Larimar Therapeutics, Inc. (NASDAQ: LRMR) resulting from allegations that Larimar Therapeutics may have issued materially misleading business information to the investing public. So What: If you purchased Larimar Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs throu. ...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Designer Brands Inc. (NYSE: DBI) resulting from allegations that Designer Brands may have issued materially misleading business information to the investing public. So What: If you purchased Designer Brands securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fe. ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Simulations Plus, Inc. due to allegations of materially misleading business information issued to the investing public [1] Group 1 - The investigation is focused on the potential impact of misleading information on Simulations Plus shareholders [1] - Shareholders who purchased Simulations Plus securities may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [1]

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) resulting from allegations that MoonLake may have issued materially misleading business information to the investing public. So What: If you purchased MoonLake securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar. ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Freeport-McMoRan Inc. due to allegations of materially misleading business information issued by the company [1] Group 1 - The investigation is focused on Freeport-McMoRan Inc. (NYSE: FCX) and its potential misrepresentation of business information to the investing public [1] - Shareholders who purchased Freeport securities may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [1]

Core Viewpoint - CarMax, Inc. is under investigation for potential violations of federal securities laws following disappointing earnings reports and claims of misleading statements regarding demand for its vehicles [1][2]. Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is leading the investigation into CarMax for possible securities law violations [1]. - The investigation is prompted by CarMax's claims of strong demand for used cars, which may have been artificially inflated due to pre-tariff purchasing behavior [2]. Group 2: Financial Performance - In fiscal Q2 2025, CarMax reported a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [3]. - The company's net earnings for Q2 were approximately $95.4 million, down from $132.8 million in the previous year, attributed to a "pull forward" in demand due to tariff announcements [3]. - Following the earnings report, CarMax's stock price dropped by $11.45 per share, or about 20%, from $57.05 on September 24, 2025, to $45.60 on September 25, 2025 [3].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Synopsys, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Performance - On September 9, 2025, Synopsys released its financial results for the third quarter of fiscal year 2025, where the CEO acknowledged that the IP business underperformed expectations [4]. - Following the earnings announcement, Synopsys shares fell by $216.59 per share, or 35.8%, closing at $387.78 on September 10, 2025, after missing both top and bottom-line consensus estimates [4]. Group 2: Legal Actions - Investors who purchased Synopsys securities may be entitled to compensation through a class action lawsuit being prepared by Rosen Law Firm, which operates on a contingency fee basis [2]. - The firm encourages investors to select qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [5].

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Synopsys, Inc. (NASDAQ: SNPS) resulting from allegations that Synopsys may have issued materially misleading business information to the investing public. So What: If you purchased Synopsys securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Th. ...